New Management Strategy of Pregnancies at Risk of Congenital Adrenal Hyperplasia Using Fetal Sex Determination in Maternal Serum: French Cohort of 258 Cases (2002–2011) | Zendy

Véronique Tardy-Guidollet | Zendy; Rita Menassa | Zendy; JeanMarc Costa | Zendy; M David | Zendy; Claire Bouvattier-Morel | Zendy; Clarisse Baumann | Zendy; Muriel Houang | Zendy; F. Lorenzini | Zendy; Nicole Philip | Zendy; Sylvie Odent | Zendy; Agnès Guichet | Zendy; Yves Morel | Zendy

Open Access

New Management Strategy of Pregnancies at Risk of Congenital Adrenal Hyperplasia Using Fetal Sex Determination in Maternal Serum: French Cohort of 258 Cases (2002–2011)

Author(s) -

Véronique Tardy-Guidollet,

Rita Menassa,

JeanMarc Costa,

M David,

Claire Bouvattier-Morel,

Clarisse Baumann,

Muriel Houang,

F. Lorenzini,

Nicole Philip,

Sylvie Odent,

Agnès Guichet,

Yves Morel

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-2895

Subject(s) - virilization , congenital adrenal hyperplasia , medicine , obstetrics , gestation , fetus , pregnancy , testis determining factor , prenatal diagnosis , amniocentesis , gynecology , endocrinology , androgen , biology , hormone , biochemistry , y chromosome , gene , genetics

Prenatal dexamethasone (DEX) treatment has been proposed since 1984 to prevent genital virilization in girls with congenital adrenal hyperplasia (CAH). DEX is effective in CAH females if initiated before the sixth week of gestation, but its safety in children treated in utero remains controversial regarding cognitive functions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research